Boehringer’s OFEV slows IPF disease progression by half in trials

pharmafile | February 26, 2016 | News story | Research and Development, Sales and Marketing Boehringer Ingelheim, IPF, ofev 

Boehringer Ingelheim has revealed pooled analysis data from three trials, showing that its drug OFEV significantly reduces the risk of acute exacerbations by 47% in people with the rare lung disease idiopathic pulmonary fibrosis (IPF).

An acute exacerbation is the name given to a sudden unexplained worsening in respiratory function – a leading cause of hospitalisation IPF patients. The trial findings are significant as around half of all people hospitalised because of an acute IPF exacerbation die in hospital, but the new data show OFEV reduced this fatality risk and slowed disease progression by approximately 50% across a broad range of patient types.

The pooled analysis was from data from the Phase II TOMORROW trial and the two Phase III INPULSIS trials of a total 1,231 people with IPF. Of these, 723 were treated with OFEV, and 508 with placebo). Data from these three clinical trials led to OFEVs approval for IPF in the US, Europe, Japan and other countries worldwide in 2014 and 2015. OFEV is also widely approved to treat lung cancer.

The one-year combined data showed OFEV reduced the risk of an acute IPF exacerbation by 47%, compared to placebo, slowed disease progression some 50% and reduced risk of death from any cause by 30%.

“Reducing the risk of exacerbations is an important treatment goal in the management of idiopathic pulmonary fibrosis because of their unpredictability and devastating impact on the course of the disease. Acute exacerbations often lead to death within a few months,” says Luca Richeldi, Professor of Respiratory Medicine at the University of Southampton, UK. “Analyses like these add to the growing body of evidence that we may see people with IPF live longer because recently approved treatments have an impact on the course of the disease.”

Joel Levy

Related Content

FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment

Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) …

Boehringer Ingelheim and Ginkgo Bioworks collaborate over $406m undruggable targets deal

German pharmaceutical company Boehringer Ingelheim (BI) and cell programming and biosecurity platform builder Ginkgo Bioworks …


Researchers and pharma companies partner to investigate new schizophrenia treatment

The University of Oxford, the Earlham Institute, and global pharmaceutical companies Biogen and Boehringer Ingelheim …

Latest content